Dr Fabio Liberante | Postdoctoral Fellow

Liberante, Fabio


Fabio is a postdoctoral fellow in the newly-founded Synthetic Genomics programme at the Wellcome Sanger Institute. Fabio will provide expertise in genome engineering and help build better models to study genetic diseases, such as cancer.

While Fabio will initially be sited within David Adams group at Sanger, the programme involves associate faculty from leading groups in Synthetic biology: Tom Ellis, Jason Chin, Patrick Cai and Kaihang Wang

Publications

  • Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.

    Liberante FG, Lappin K, Barros EM, Vohhodina J, Grebien F et al.

    Scientific reports 2019;9;1;2678

  • Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

    Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E et al.

    Leukemia 2016;30;12;2322-2331

  • An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping.

    Thillaiyampalam G, Liberante F, Murray L, Cardwell C, Mills K and Zhang SD

    BMC bioinformatics 2017;18;1;581

  • The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export.

    Vohhodina J, Barros EM, Savage AL, Liberante FG, Manti L et al.

    Nucleic acids research 2017;45;22;12816-12833

  • Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    Liberante FG, Pouryahya T, McMullin MF, Zhang SD and Mills KI

    Oncotarget 2016;7;6;6609-19

  • High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.

    Liberante FG, Pellagatti A, Boncheva V, Bowen DT, Mills KI et al.

    British journal of haematology 2013;162;2;282-5

  • The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells.

    Clarke K, Young C, Liberante F, McMullin MF, Thompson A and Mills K

    Oncotarget 2019;10;37;3462-3471

  • Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.

    Liberante FG, Lappin K, Barros EM, Vohhodina J, Grebien F et al.

    Scientific reports 2019;9;1;2678

  • Postdiagnostic Calcium Channel Blocker Use and Breast Cancer Mortality: A Population-based Cohort Study.

    Busby J, Mills K, Zhang SD, Liberante FG and Cardwell CR

    Epidemiology (Cambridge, Mass.) 2018;29;3;407-413

  • Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.

    Busby J, Mills K, Zhang SD, Liberante FG and Cardwell CR

    Breast cancer research : BCR 2018;20;1;4

  • A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties.

    Busby J, Murray L, Mills K, Zhang SD, Liberante F and Cardwell CR

    Pharmacoepidemiology and drug safety 2018;27;1;78-86

  • An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping.

    Thillaiyampalam G, Liberante F, Murray L, Cardwell C, Mills K and Zhang SD

    BMC bioinformatics 2017;18;1;581

  • The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export.

    Vohhodina J, Barros EM, Savage AL, Liberante FG, Manti L et al.

    Nucleic acids research 2017;45;22;12816-12833

  • Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.

    Hay JF, Lappin K, Liberante F, Kettyle LM, Matchett KB et al.

    Oncotarget 2017;8;40;67891-67903

  • Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

    Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E et al.

    Leukemia 2016;30;12;2322-2331

  • Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    Liberante FG, Pouryahya T, McMullin MF, Zhang SD and Mills KI

    Oncotarget 2016;7;6;6609-19

  • Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.

    Kettyle LM, Liberante FG and Thompson A

    Methods in molecular biology (Clifton, N.J.) 2014;1196;349-70

  • HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.

    Dickson GJ, Liberante FG, Kettyle LM, O'Hagan KA, Finnegan DP et al.

    Haematologica 2013;98;8;1216-25

  • High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.

    Liberante FG, Pellagatti A, Boncheva V, Bowen DT, Mills KI et al.

    British journal of haematology 2013;162;2;282-5

  • Cell survival responses after exposure to modulated radiation fields.

    Trainor C, Butterworth KT, McGarry CK, Liberante F, O'Sullivan JM et al.

    Radiation research 2012;177;1;44-51

  • Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8.

    Chacko AD, Liberante F, Paul I, Longley DB and Fennell DA

    BMC cancer 2010;10;380

Liberante, Fabio